Cardiol Therapeutics (CRDL) Stock Price, News & Analysis

Company Overview

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes. The company is preparing to initiate further Phase 2 trials in patients with heart failure and preserved ejection fraction to explore the potential of CBD-based therapy to reduce hospitalization rates and improve quality of life. In parallel, Cardiol is investigating novel cyclic dinucleotide immunomodulators designed to recalibrate the innate immune response in cardiovascular settings.

Headquartered in Toronto, Canada, Cardiol Therapeutics operates multiple clinical and research collaborations across North America and Europe. Founded in 2017 and rebranded in 2019 after acquiring its core CBD assets, the company is led by Executive Chairman Peter Hamilton, a seasoned life-science executive, alongside a management team with deep expertise in drug development, regulatory affairs, and cardiovascular research. Cardiol’s strategy emphasizes translational science and collaborative clinical programs to address critical unmet needs in heart disease.

Key Stats

• Today's Range: $1.03 to $1.08
• 50-Day Range: $1.03 to $1.63
• 52-Week Range: $0.88 to $1.71
• Volume: 288,383 shs
• Average Volume: 351,527 shs
• Market Capitalization: $118.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Hold

Cardiol Therapeutics Stock Analysis - MarketRank™

Cardiol Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 539th out of 862 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Cardiol Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Cardiol Therapeutics has a consensus price target of $8.50, representing about 725.2% upside from its current price of $1.03.

Amount of Analyst Coverage

Cardiol Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Cardiol Therapeutics are expected to remain at ($0.31) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cardiol Therapeutics is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cardiol Therapeutics is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cardiol Therapeutics has a P/B Ratio of 9.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.76% of the float of Cardiol Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cardiol Therapeutics has a short interest ratio ("days to cover") of 6.44.

Change versus previous month

Short interest in Cardiol Therapeutics has recently decreased by 2.08%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cardiol Therapeutics does not currently pay a dividend.

Dividend Growth

Cardiol Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: N/A

News Sentiment

Cardiol Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Cardiol Therapeutics this week, compared to 2 articles on an average week.

Search Interest

7 people have searched for CRDL on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.

MarketBeat Follows

4 people have added Cardiol Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cardiol Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.25% of the stock of Cardiol Therapeutics is held by insiders.

Percentage Held by Institutions

12.49% of the stock of Cardiol Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/11/2026
• Today: 6/13/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRDL
• CIK: 1702123
• Web: www.cardiolrx.com
• Phone: (289) 910-0850
• Fax: N/A
• Employees: 20
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Cardiol Therapeutics: $8.50
• High Price Target: $9.00
• Low Price Target: $8.00
• Potential Upside/Downside: +725.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.20 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -229.43%
• Return on Assets: -165.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.39
• Quick Ratio: 4.39

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.11 per share
• Price / Book: 9.36

Miscellaneous

• Outstanding Shares: 115,250,000
• Free Float: 109,195,000
• Market Cap: $118.71 million
• Optionable: Not Optionable
• Beta: 0.72